These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 12874970)

  • 1. The money men.
    Alper J
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE7-12. PubMed ID: 12874970
    [No Abstract]   [Full Text] [Related]  

  • 2. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 3. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 4. The term sheet tango.
    Willey T; Parsigian D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
    [No Abstract]   [Full Text] [Related]  

  • 5. Boutiques reborn in 2003.
    Surendran A
    Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 7. The habits of successful bioentrepreneurs.
    Hodgson J; Ward M
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE3-5. PubMed ID: 12874969
    [No Abstract]   [Full Text] [Related]  

  • 8. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 9. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 10. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 11. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 12. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 13. Intellectual property as a foundation for funding.
    Meltzer SL; Marks MS; McCormick JT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE47-50. PubMed ID: 12089588
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 15. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 16. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 17. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 18. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 19. The future of biotechnology funding: An interview with venture capitalist Dennis Purcell. Interviewed by Elaine Musgrave.
    Purcell D
    Clin Transl Sci; 2009 Oct; 2(5):320-1. PubMed ID: 20443914
    [No Abstract]   [Full Text] [Related]  

  • 20. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.